Literature DB >> 7681439

Two highly antigenic sites in the human immunodeficiency virus type 1 reverse transcriptase.

E Björling1, C A Boucher, A Samuelsson, T F Wolfs, G Utter, E Norrby, F Chiodi.   

Abstract

Antibodies to human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) are found in the serum of the majority of infected individuals, and inhibition of RT polymerase activity by HIV-1-positive sera can be demonstrated in vitro. The binding sites of human antibodies on the protein have not yet been identified. We synthesized overlapping peptides covering the entire RT protein of HIV-1 and used them in an enzyme-linked immunosorbent assay system to map the reactivities of HIV-1 and HIV-2 antibody-positive sera. Two highly antigenic regions were identified by both HIV serotypes. One region was found in the central part of the RT protein (amino acids 261 to 280) and another was found at the carboxy terminus in the RNase H portion of RT (amino acids 517 to 536). Comparison of the serological results with the crystal structure of the RT revealed that the antigenic region in the RNase H portion is located at the surface of the protein. The other antibody-binding site (amino acids 261 to 280) was located in the "thumb" region of the polymerase domain of RT. Polyclonal antibodies to either of the antibody-binding sites do not affect the polymerase activity of the RT protein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7681439      PMCID: PMC262825          DOI: 10.1128/jcm.31.3.588-592.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids.

Authors:  R A Houghten
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

2.  Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.

Authors:  F di Marzo Veronese; T D Copeland; A L DeVico; R Rahman; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1986-03-14       Impact factor: 47.728

3.  Immunogenic nature of a Pol gene product of HTLV-III/LAV.

Authors:  J S Allan; J E Coligan; T H Lee; F Barin; P J Kanki; S M'Boup; M F McLane; J E Groopman; M Essex
Journal:  Blood       Date:  1987-01       Impact factor: 22.113

Review 4.  Prediction of the secondary structure of proteins from their amino acid sequence.

Authors:  P Y Chou; G D Fasman
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1978

5.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

6.  Susceptibility to infection by the human immunodeficiency virus (HIV) correlates with T4 expression in a parental monocytoid cell line and its subclones.

Authors:  B Asjö; I Ivhed; M Gidlund; S Fuerstenberg; E M Fenyö; K Nilsson; H Wigzell
Journal:  Virology       Date:  1987-04       Impact factor: 3.616

7.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.

Authors:  L A Kohlstaedt; J Wang; J M Friedman; P A Rice; T A Steitz
Journal:  Science       Date:  1992-06-26       Impact factor: 47.728

8.  Genomic diversity of human T-lymphotropic virus type III (HTLV-III).

Authors:  F Wong-Staal; G M Shaw; B H Hahn; S Z Salahuddin; M Popovic; P Markham; R Redfield; R C Gallo
Journal:  Science       Date:  1985-08-23       Impact factor: 47.728

9.  Site-specific mutagenesis of AIDS virus reverse transcriptase.

Authors:  B A Larder; D J Purifoy; K L Powell; G Darby
Journal:  Nature       Date:  1987 Jun 25-Jul 1       Impact factor: 49.962

10.  Characterization and clinical association of antibody inhibitory to HIV reverse transcriptase activity.

Authors:  J Laurence; A Saunders; J Kulkosky
Journal:  Science       Date:  1987-03-20       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.